Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals
Evidence on the performance and cost-effectiveness of the Febrile Antigen Brucella Agglutination Test compared to the Rose Bengal Test
Abstract
Hospitals in Kenya continue to use the Febrile Antigen Brucella Agglutination Test (FBAT) to diagnose brucellosis, despite reports showing its inadequacy. This study generated hospital-based evidence on the performance and cost-effectiveness of the FBAT, compared to the Rose Bengal Test (RBT).Twelve hospitals in western Kenya stored patient serum samples that were tested for brucellosis using the FBAT, and these were later re-tested using the RBT. Data on the running time and cost of the FBAT, and the treatment prescribed for brucellosis, were collected.
This is a publication arising from the Zoonoses and Emerging Livestock Systems (ZELS) programme
Citation
Alumasa L, Thomas L, Amanya F, Njoroge S, Moriyón I, Makhandia J, Rushton J, Fèvre E, Falzon L (2021). Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals. PLoS Negl Trop Dis. 15:e0008977.